Halozyme Therapeutics Inc (HALO) — Capital Reinvestment Ratio
Latest as of September 2025:
0.02x
Halozyme Therapeutics Inc (HALO) has a Capital Reinvestment Ratio of 0.02x as of September 2025, meaning it reinvests 0% of its operating cash flow ($178.60 Million) in capital expenditures ($3.03 Million). See cash generation quality of Halozyme Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.02x
Capex / Operating Cash Flow
Operating Cash Flow
$178.60 Million
USD
Capital Expenditures
$3.03 Million
USD
Data as of
Sep 2025
Most recent filing
Halozyme Therapeutics Inc Capital Reinvestment Ratio (2006–2024)
This chart tracks Halozyme Therapeutics Inc's Capital Reinvestment Ratio across 7 annual periods.
Annual Capital Reinvestment Ratio for Halozyme Therapeutics Inc (2006–2024)
Year-by-year Capital Reinvestment Ratio for Halozyme Therapeutics Inc from 2006 to 2024. For live market cap and broader valuation context, see Halozyme Therapeutics Inc market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.02x | $479.06 Million | $10.70 Million | ▼ -43.3% |
| 2023 | 0.04x | $388.57 Million | $15.29 Million | ▲ +96.5% |
| 2022 | 0.02x | $240.11 Million | $4.81 Million | ▲ +311.7% |
| 2021 | 0.00x | $299.44 Million | $1.46 Million | ▼ -89.2% |
| 2020 | 0.05x | $55.45 Million | $2.50 Million | ▲ +348.4% |
| 2017 | 0.01x | $134.05 Million | $1.35 Million | ▼ -80.5% |
| 2006 | 0.05x | $7.08 Million | $364.80K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow